secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-099328
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio reports Q4 net income of $57.7M; Phase 2a SIGNAL-AA enrollment complete; cash runway into Q4 2027
--------------------------------------------------------------------------------

- Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.
- Completed $10.5M registered direct offering in Feb 2026; cash $48.3M at Dec 31, 2025, plus RDO and milestones fund ops into Q4 2027.
- Sold ADX-097 to Akebia Therapeutics for $12M upfront/near-term milestone; up to $592M in milestones plus royalties.
- Terminated all remaining obligations to Amgen via one-time equity grant; no future payments to Amgen.
- Net income $57.7M in Q4 2025 and $29.8M for FY 2025 vs net loss prior year; EPS $4.58 diluted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526099328/0001193125-26-099328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526099328/qttb-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-099328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer